TrialNature medicine2022

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

Spyros Chalkias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.